Harrow
Commercializes branded eye medicines and ImprimisRx compounding for US ophthalmology.
$37.77
After-hours close+0.48 (+1.29%)
At close$37.29(−3.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 62.65%23.35M sharesInsiders 11.48%4.28M sharesOther 25.87%9.64M shares
Shares outstanding 37.28M · Float 28.72M · 77.0% free float
Institutions13F, as of Jun 30, 2026
233 holders · 23.35M shares · 44 new positions · 122 increased · 66 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.74M | 7.35% | +187.4K | Aug 7, 2026 |
| Opaleye Management Inc. | 2.40M | 6.44% | −432.2K | Aug 14, 2026 |
| Private Capital Management, LLC | 1.60M | 4.29% | +36.8K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.42M | 3.80% | +14.2K | Aug 13, 2026 |
| Deep Track Capital, LP | 969.0K | 2.60% | +969.0Knew | Aug 14, 2026 |
| State Street Corp | 939.9K | 2.52% | +84.8K | Aug 7, 2026 |
| Geode Capital Management, LLC | 905.6K | 2.43% | +53.5K | Aug 12, 2026 |
| Bamco Inc /NY/ | 809.4K | 2.17% | +809.4Knew | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Mark L. Baum | 10.69% | 4.06M | 13D | Apr 7, 2025 ↗ |
| Opaleye Management Inc. | 7.61% | 2.83M | 13G | May 11, 2026 ↗ |
| Daniel Kaufman | 5.04% | 1.88M | 13G | Mar 11, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Mark L. Baum | director, officer: CHIEF EXECUTIVE OFFICER | 3.00M | 8.04% | May 15, 2026 |
| Andrew R. Boll | officer: PRESIDENT AND CFO | 814.7K | 2.19% | May 15, 2026 |
| John P. Saharek | officer: CEO & President, ImprimisRx | 467.4K | 1.25% | Apr 7, 2025 |
| Opaleye Management Inc. | 10 percent owner | 59.4K | 0.16% | Mar 5, 2026 |
| Adrienne L. Graves | director | 1.0K | 0.00% | May 19, 2026 |
| Lauren P. Silvernail | director | 1.0K | 0.00% | May 19, 2026 |
4 ten-percent owners hold 1.76M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 15 people have not refiled in the last 18 months (1.20M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Amir Shojaeiofficer: CHIEF SCIENTIFIC OFFICER | Sale | 11,250 | $40.00 | 0 |
| May 18, 2026 | Lauren P. Silvernaildirector | Purchase | 1,000 | $31.00 | 1,000 |
| May 18, 2026 | Adrienne L. Gravesdirector | Purchase | 1,000 | $31.07 | 1,000 |
| May 14, 2026 | Andrew R. Bollofficer: PRESIDENT AND CFO | Purchase | 3,500 | $29.90 | 814,679 |
| May 14, 2026 | Mark L. Baumdirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 10,000 | $30.20 | 2,996,130 |
| Mar 4, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 138,263 | $39.67 | 59,428 |
| Mar 3, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 60,309 | $39.15 | 63,691 |
| Feb 27, 2026 | Opaleye Management Inc.10 percent owner | Sale | 5,000 | $54.18 | 65,000 |
| Jan 6, 2026 | Opaleye Management Inc.10 percent owner | Sale | 20,000 | $53.35 | 70,000 |
CongressHouse and Senate disclosures
Not reported.